MX2023001002A - Farmacos antivirales, composiciones farmaceuticas, y metodos. - Google Patents

Farmacos antivirales, composiciones farmaceuticas, y metodos.

Info

Publication number
MX2023001002A
MX2023001002A MX2023001002A MX2023001002A MX2023001002A MX 2023001002 A MX2023001002 A MX 2023001002A MX 2023001002 A MX2023001002 A MX 2023001002A MX 2023001002 A MX2023001002 A MX 2023001002A MX 2023001002 A MX2023001002 A MX 2023001002A
Authority
MX
Mexico
Prior art keywords
methods
pharmaceutical formulations
compounds
antiviral prodrugs
prodrugs
Prior art date
Application number
MX2023001002A
Other languages
English (en)
Inventor
Nadejda Valiaeva
Robert T Schooley
Karl Y Hostetler
James Beadle
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of MX2023001002A publication Critical patent/MX2023001002A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/06—Heterocyclic radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
    • C07F9/6574—Esters of oxyacids of phosphorus
    • C07F9/65744—Esters of oxyacids of phosphorus condensed with carbocyclic or heterocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C07H1/02—Phosphorylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H9/00—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical
    • C07H9/02—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical the hetero ring containing only oxygen as ring hetero atoms

Abstract

La presente se refiere a compuestos, que incluyen profármacos antivirales, y formulaciones farmacéuticas que incluyen los compuestos, que pueden estar biodisponibles por vía oral o formularse para inyección intramuscular. Métodos para producir compuestos, tales como profármacos antivirales. Métodos para tratar la infección por coronavirus y otros virus de ARN en mamíferos. Métodos para producir un fármaco de trifosfato.
MX2023001002A 2020-07-24 2021-07-24 Farmacos antivirales, composiciones farmaceuticas, y metodos. MX2023001002A (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202063055944P 2020-07-24 2020-07-24
US202063070695P 2020-08-26 2020-08-26
US202063078427P 2020-09-15 2020-09-15
US202063110596P 2020-11-06 2020-11-06
US202163145698P 2021-02-04 2021-02-04
PCT/US2021/043094 WO2022020793A1 (en) 2020-07-24 2021-07-24 Antiviral prodrugs, pharmaceutical formulations, and methods

Publications (1)

Publication Number Publication Date
MX2023001002A true MX2023001002A (es) 2023-03-01

Family

ID=79728410

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023001002A MX2023001002A (es) 2020-07-24 2021-07-24 Farmacos antivirales, composiciones farmaceuticas, y metodos.

Country Status (9)

Country Link
US (1) US20230287029A1 (es)
EP (1) EP4185300A1 (es)
JP (1) JP2023535065A (es)
CN (1) CN116264827A (es)
AU (1) AU2021312946A1 (es)
BR (1) BR112023001129A2 (es)
CA (1) CA3186881A1 (es)
MX (1) MX2023001002A (es)
WO (1) WO2022020793A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4200301A1 (en) 2020-08-24 2023-06-28 Gilead Sciences, Inc. Phospholipid compounds and uses thereof
TWI811812B (zh) 2020-10-16 2023-08-11 美商基利科學股份有限公司 磷脂化合物及其用途
AU2022328698A1 (en) * 2021-08-18 2024-02-01 Gilead Sciences, Inc. Phospholipid compounds and methods of making and using the same
CN116554249A (zh) * 2022-01-28 2023-08-08 北京恩泰伟医药科技有限公司 抗病毒化合物及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011130557A2 (en) * 2010-04-14 2011-10-20 The Regents Of The University Of California Phosphonates with reduced toxicity for treatment of viral infections
CN108619161A (zh) * 2013-03-15 2018-10-09 加利福尼亚大学董事会 无环核苷膦酸二酯
TWI740546B (zh) * 2014-10-29 2021-09-21 美商基利科學股份有限公司 製備核糖苷的方法
WO2017156380A1 (en) * 2016-03-10 2017-09-14 Emory University N4-hydroxycytidine and derivatives and anti-viral uses related thereto
CR20200126A (es) * 2017-09-18 2020-07-11 Janssen Biopharma Inc Nucleósidos sustituidos, nucleótidos y análogos de estos

Also Published As

Publication number Publication date
AU2021312946A1 (en) 2023-03-09
EP4185300A1 (en) 2023-05-31
CA3186881A1 (en) 2022-01-27
BR112023001129A2 (pt) 2023-02-14
US20230287029A1 (en) 2023-09-14
JP2023535065A (ja) 2023-08-15
CN116264827A (zh) 2023-06-16
WO2022020793A1 (en) 2022-01-27

Similar Documents

Publication Publication Date Title
MX2023001002A (es) Farmacos antivirales, composiciones farmaceuticas, y metodos.
ZA202307575B (en) Methods and modified nucleosides for treating coronavirus infections
CR20220109A (es) Profármacos antivirales y formulaciones de los mismos
PH12018550148A1 (en) Hepatitis b antiviral agents
AU2018256602A1 (en) Functionalized benzamide derivatives as antiviral agents against hbv infection
MX2019007585A (es) Profarmacos de ester alifatico antiviricos de tenofovir.
CL2021002747A1 (es) Agentes antivirales para la hepatitis b (solicitud divisional no. 487-2020)
MX2022000563A (es) Derivado de adenosina y composición farmacéutica que lo comprende.
UY28084A1 (es) Derivados antivirales de nucleosidos
BR112018009009A2 (pt) terapia combinada de um inibidor de formação de capsídeo hbv e um interferon
MX2011007364A (es) Derivados de fosforamidato de compuestos de nuecleosido de guanosina para tratamiento de infecciones virales.
WO2009123776A3 (en) Antiviral drugs for treatment of arenavirus infection
WO2004074270A3 (en) Inhibitors of hepatitis c virus rna-dependent rna polymerase, and compositions and treatments using the same
ECSP13010937A (es) Compuestos antivirales
CR8935A (es) Inhibidores de la arn polimerasa dependiente del arn del virus de la hepatitis c y composiciones
CL2008003431A1 (es) Compuestos derivados de nucleosidos 2',4' sustituidos; proceso de preparacion de dichos compuestos; composicion farmaceutica que los comprende; su metodo de preparacion; y su uso para el tratamiento y/o la prevencion de cualquier condicion resultante de una infeccion por vhb, vhc o vih.
CR20220675A (es) Análogos de nucleósido de 1´- ciano y usos de los mismos
MY197236A (en) 2'-substituted-n6-substituted purine nucleotides for rna virus treatment
ES2510940A2 (es) Composición farmacéutica combinada y su uso para preparar un medicamento destinado al tratamiento y prevención de las enfermedades infecciosas
BR112017000320A2 (pt) métodos para o tratamento de infecções virais de hepatite b e hepatite d
CR20230100A (es) Compuestos fosfolípidos y usos de los mismos
BR112018015629A2 (pt) ?composto, composição, método para tratar um mamífero infectado com o vírus hiv, e, proteína mutante tripla?
MX2022011885A (es) Composicion farmaceutica para la prevencion o tratamiento de enfermedad infecciosa viral de arn epidemica.
MX2023008004A (es) Derivado de adenosina y composicion farmaceutica que lo comprende.
WO2009129798A3 (de) Di- und triphosphat-prodrugs, insbesondere nukleosiddi- und -triphosphat-prodrugs